CLOs on the Move

ScribeAmerica

www.scribeamerica.com

 
ScribeAmerica is a Lancaster, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Optum

Optum is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. Optum comprises three companies â€" OptumHealth, OptumInsight and OptumRx â€" representing more than 35,000 employees worldwide who collaborate to deliver integrated, intelligent solutions that work to modernize the health system and improve overall population health.

OSU Medical Center

The Ohio State University Medical Center (OSUMC) is a multidisciplinary academic medical center located in Columbus, Ohio

Battle Creek Health System

Battle Creek Health System (BCHS) is a multi-campus health care provider serving approximately 200,000 people in south central Michigan. BCHS was formed through the merger of Battle Creek's two acute care hospitals-Leila Y. Post Montgomery Hospital and

North Valley Health Center

North Valley Health Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. North Valley Health Center is based in Warren, MN. You can find more information on North Valley Health Center at www.nvhc.net

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.